Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:

• How the experts currently use CDK4/6 inhibitors in clinical practice
• Clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021
• Strategies for counseling patients receiving CDK4/6 inhibitors

Presenters:

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.
Professor of Oncology and Pharmacology
Director, Mayo Clinic Breast Cancer SPORE
Co-Leader, Women's Cancer Program, Mayo Clinic Cancer Center
Co-Chair, Mayo Breast Disease Group
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Link to the full program:
bit.ly/3kaJKeC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.